GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » EV-to-EBITDA

AIM ImmunoTech (STU:HXB2) EV-to-EBITDA : -0.28 (As of May. 11, 2024)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AIM ImmunoTech's enterprise value is €8.06 Mil. AIM ImmunoTech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-28.81 Mil. Therefore, AIM ImmunoTech's EV-to-EBITDA for today is -0.28.

The historical rank and industry rank for AIM ImmunoTech's EV-to-EBITDA or its related term are showing as below:

STU:HXB2' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.16   Med: -1.4   Max: 1
Current: -0.28

During the past 13 years, the highest EV-to-EBITDA of AIM ImmunoTech was 1.00. The lowest was -6.16. And the median was -1.40.

STU:HXB2's EV-to-EBITDA is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 9.53 vs STU:HXB2: -0.28

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), AIM ImmunoTech's stock price is €0.402. AIM ImmunoTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.555. Therefore, AIM ImmunoTech's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


AIM ImmunoTech EV-to-EBITDA Historical Data

The historical data trend for AIM ImmunoTech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech EV-to-EBITDA Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.49 -3.04 0.18 0.90 -0.31

AIM ImmunoTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.41 -0.26 -0.05 -0.31

Competitive Comparison of AIM ImmunoTech's EV-to-EBITDA

For the Biotechnology subindustry, AIM ImmunoTech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's EV-to-EBITDA falls into.



AIM ImmunoTech EV-to-EBITDA Calculation

AIM ImmunoTech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.063/-28.806
=-0.28

AIM ImmunoTech's current Enterprise Value is €8.06 Mil.
AIM ImmunoTech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech  (STU:HXB2) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

AIM ImmunoTech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.402/-0.555
=At Loss

AIM ImmunoTech's share price for today is €0.402.
AIM ImmunoTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.555.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


AIM ImmunoTech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines